Mainland China revenue trends and regulatory environment - historically 30-40% of total revenue, subject to direct-selling license restrictions and government crackdowns on MLM practices
Active distributor count and productivity metrics - total distributor base size, sales leaders (high-volume distributors), average revenue per distributor
New product launch success rates - particularly ageLOC beauty device adoption and Pharmanex supplement line extensions that drive distributor excitement and recruitment
Currency fluctuations in key markets - significant exposure to Chinese yuan, Korean won, Japanese yen with limited hedging programs
moderate-to-high - Premium discretionary personal care and supplements are economically sensitive purchases. Distributor recruitment slows during recessions as side-income opportunities become less attractive. However, MLM models can paradoxically see recruitment spikes during early recession phases as unemployed workers seek income alternatives. Consumer spending weakness in China (50%+ of revenue exposure) directly impacts results. The -14.3% revenue decline suggests cyclical vulnerability.
Low direct sensitivity as the company carries modest debt (0.45x D/E) and generates positive free cash flow. However, rising rates indirectly pressure valuation multiples for cash-generative businesses and may reduce distributor willingness to invest in inventory purchases if consumer credit tightens. Distributor financing for starter kits and inventory can be affected by consumer credit availability.
Secular decline in MLM business model legitimacy - regulatory scrutiny intensifying globally, particularly in China where government has periodically restricted direct-selling licenses. Younger consumers increasingly view MLM as pyramid schemes, limiting recruitment pipeline
E-commerce and social media disruption - Traditional MLM face-to-face selling model losing relevance as consumers shift to Amazon, Sephora, and direct-brand websites. Digital-native brands (The Ordinary, Glossier) capture anti-aging market share at lower price points
China regulatory risk - Direct-selling licenses subject to arbitrary government restrictions, with precedent of multi-month business suspensions. Geopolitical tensions could trigger targeted enforcement against US-based MLM companies
value/special situations - The 0.3x P/S and 0.5x P/B ratios attract deep-value investors betting on business stabilization or activist intervention. 11.1% FCF yield appeals to income-focused value investors. High ROE (20.4%) despite distressed valuation suggests potential for mean reversion if operational challenges resolve. Not suitable for growth or ESG investors given structural MLM model concerns and negative revenue growth. Recent 210% EPS growth from depressed base may attract momentum traders, but underlying revenue decline limits sustainability.
Trend
-16.6% vs SMA 50 · -36.9% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $1.8B $1.8B–$1.8B | — | -$2.99 | — | — | Low1 |
FY2024 | $1.7B $1.7B–$1.7B | ▼ -6.6% | $0.68 | — | ±2% | Low2 |
FY2025 | $1.5B $1.5B–$1.5B | ▼ -13.1% | $1.30 | ▲ +92.6% | — | Low1 |
Dividend per payment — last 8 periods
INSTITUTIONAL OWNERSHIP
NUS News
About
founded 35 years ago, nu skin enterprises, inc. (nse) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies, and life-improving values. the company currently focuses its efforts around innovative consumer products, product manufacturing and automated controlled environment agriculture technology. the nse family of companies includes: nu skin, groviv, wasatch labs, elevate health sciences, and casepak. nu skin enterprises is traded on the new york stock exchange under the symbol "nus." more information is available at nuskinenterprises.com.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
NUS◀ | $6.12 | -2.55% | $297M | 5.4 | -1425.6% | 1078.7% | 1500 |
| $131.45 | -0.76% | $1.0T | 47.9 | +472.5% | 307.0% | 1520 | |
| $1048.95 | +0.74% | $465.4B | 54.5 | +816.7% | 294.3% | 1507 | |
| $80.82 | +0.46% | $347.7B | 25.4 | +187.0% | 2734.0% | 1508 | |
| $141.57 | -0.80% | $329.7B | 20.5 | +29.2% | 1895.3% | 1486 | |
| $189.61 | -1.17% | $295.5B | 26.7 | +731.3% | 2791.8% | 1509 | |
| $149.12 | +0.30% | $203.8B | 23.3 | +225.5% | 877.3% | 1488 | |
| Sector avg | — | -0.54% | — | 29.1 | +148.1% | 1425.5% | 1503 |